Retrospective study of 80 kids w/ systemic JIA - 12 pts changed anakinra to cananinumab & continued w/ clinical inactive Dz (CID). 68 active sJIA Rx w/ CAN: 57% CID off GCs at 6 mos & 64% at 12 mos. NonResponse predicted by #active jts ≥5, hx of MAS https://t.co/QkmqzRrjp6